<DOC>
	<DOC>NCT01457768</DOC>
	<brief_summary>This Registry is designed to obtain long term data on participants who have failed to achieve sustained virologic response (SVR) while receiving at least one Gilead oral antiviral agent (OAV) in a previous Gilead-sponsored hepatitis C virus (HCV) study.</brief_summary>
	<brief_title>A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Have previously participated in a Gileadsponsored hepatitis C study and received at least one Gilead OAV Have failed to achieve an SVR in a previous Gileadsponsored study, as defined in the original treatment protocol Provide written, informed consent Be willing and able to comply with the visit schedule Individuals planning to start a new course of hepatitis C therapy including any investigational drug or device during the course of the followup Registry History of clinically significant illness or any other major medical disorder that may interfere with followup, assessments or compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Tegobuvir</keyword>
	<keyword>Registry</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>Treatment experienced</keyword>
	<keyword>Treatment naive</keyword>
	<keyword>GS 9451</keyword>
	<keyword>GS 5885</keyword>
	<keyword>Sequence</keyword>
	<keyword>GS 5816</keyword>
	<keyword>GS 7977</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Sovaldiâ„¢</keyword>
	<keyword>SOF</keyword>
	<keyword>Ledipasvir</keyword>
	<keyword>LDV</keyword>
</DOC>